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Abstract 
Caspase recruitment domain family, member 10, 
CARD10 (also known as CARMA3 or Bimp1), is a 
member of the membrane-associated guanylate 
kinase (MAGUK) superfamily proteins that act to 
organize signaling at the plasma membrane. This 
family of proteins contains Src-homology 3 (SH3), 
PDZ, GuK domains and caspase recruitment domain 
(CARD). The amino-terminally located CARD of 
CARD10 functions as an activator of BCL10 and 
NF-kappaB (NF-kB) signaling critical for the 
regulation of cellular survival and proliferation. 
CARD10 (CARMA3) is reported to be over-
expressed in various cancer types that include breast, 
glioma, colon and non-small-cell lung cancers. It 
appears that the over-expression of CARD10 
correlates with tumor status positioning CARD10 as 
a novel therapeutic target for the treatment of various 
cancers. 
Keywords 
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Identity 
Other names: BIMP1, CARMA3 
HGNC (Hugo): CARD10 
Location: 22q13.1 
DNA/RNA 
Description 
The human CARD10 gene (NM_014550) contains 
20 exons and the encoding sequence is 3099 bases. 
Pseudogene 
No reported pseudogene. 
Protein 
Description 
CARD10 (NP_055365) is a 1032 amino-acid long 
protein with a molecular mass of 116 kDa.  
This protein consists of antiparallel alpha helices. 
CARD10 contains an N-terminal CARD domain, 
followed by a central coiled-coil (CC) domain and a 
C-terminal region encompassing a PDZ domain, a 
SH3 domain and a GUK domain (Wang et al., 2001). 
The CARD domain has a hydrophobic core and a 
hydrophilic outer surface, which mediate the 
interaction with the CARD domain of other proteins 
(Hayes-Bouchier et al., 2002; Sun, 2010). Coiled-
coil domain is responsible for dimerization (Tanner 
et al., 2007). 
Expression 
CARD10 is expressed in a variety of epithelial and 
mesenchymal tissues including heart, kidney and 
liver (Wang et al., 2001; McAllister-Lucas et al., 
2007).  
It was reported that CARD10 is over-expressed in 
several cancers including breast, ovarian, colon, lung 
and glioma cancer.  
It was also shown that CARD10 deficiency affects 
cancer cell proliferation, survival, migration and 
invasion (Jiang et al., 2011). 
Localisation 
CARD10 is localized in the cytoplasm (Li et al., 
2012). 
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The structural domains of CARD10 protein are shown in different color boxes. CARD, caspase-recruitment domain; PDZ, 
PSD95, DLGA and ZO1 homology domain; SH3 domain, SRC-homology 3; and GUK domain, guanylate kinase. The numbers 
correspond to the amino-acid sequence. 
 
Function 
CARD10 participates in the organization of 
membrane signaling involved in cellular 
proliferation and death through highly specific 
CARD-CARD homophilic interactions. It appears 
that CARD10 acting as a scaffold is involved in NF-
kB activation through interactions with Bcl10 and 
MALT1 (Grabiner et al., 2007; McAllister-Lucas et 
al., 2007). 
Homology 
CARD10 (CARMA3/Bimp1) shares a high degree 
of amino-acid sequence, structure and functional 
homology with CARD11 (CARMA1/Bimp2) and 
CARD14 (CARMA2/Bimp3). 
Mutations 
Note 
Gene mutations have not been described yet. 
Implicated in 
Breast cancer 
Disease 
The levels of CARD10 protein are reported to be 
significantly higher in breast cancer than in normal 
breast tissue.  
It appears that CARD10 over-expression correlates 
with tumor, node and metastasis (TNM) stage, tumor 
size and ErbB2, also known as HER2 (from human 
epidermal growth factor receptor 2) or HER2/neu, 
over-expression. The observations that CARD10 
leads to the up-regulation of cyclin D1, which is 
involved in proliferation, and of Bcl-2, a critical 
component in apoptosis, gene expressions in cell 
models derived from breast carcinoma (Zhao et al., 
2013) is consistent with suggestion that CARD10 is 
involved in cell survival and proliferation. 
Glioma 
Disease 
CARD10 is over-expressed in glioma and correlates 
with tumor grades (Grade I, II, III and IV) but not 
with age or gender. Knocking down of CARD10 
expression is shown to inhibit the proliferation and 
invasion of glioma cell lines (Feng et al., 2014). 
Colon cancer 
Disease 
CARD10 is also over-expressed in colon cancer 
samples compared to the normal tissue. The 
expression levels appear to associate with TNM and 
the proliferation index.  
Experimental studies suggest that CARD10 is a 
positive regulator of colon cancer proliferation 
(Miao et al., 2012). 
Renal cell carcinoma 
Disease 
CARD10 mRNA expression was found to be 
significantly higher in renal cell carcinoma tissues 
compared with noncancerous renal tissues. 
Furthermore, it was shown that the high level of the 
CARD10 gene expression is associated with tumor 
size, histological differentiation, tumor stage and the 
presence of metastasis (Wu et al., 2013). 
Ovarian cancer 
Disease 
CARD10 over-expression was observed to be 
positively correlated with tumor histology in ovarian 
cancer. It was shown that CARD10 depletion in 
various ovarian cancer cell lines inhibited cell 
proliferation and prevented cell cycle progression 
(Xie et al., 2014). It was also reported that protein 
kinase C alpha-CARD10 signaling axis plays an 
essential role in the lysophosphatidic acid (LPA)-
induced in vitro invasion of ovarian cancer cells 
(Mahanivong et al., 2008). 
Pancreatic carcinoma 
Note 
CARD10 was reported to be over-expressed in 
human pancreatic cancer (Du et al., 2014). 
Moreover, CARD10 appears to regulate malignant 
cell growth, invasion and NF-kB signaling (Du et al., 
2014). 
Non-small-cell lung cancer 
Disease 
As in other tissue cancers, the level of CARD10 
protein is higher in non-small-cell lung cancer 
(NSCLC) than in normal lung tissues. There is a 
significant correlation between CARD10 levels and 
TNM stage (Li et al., 2012). 
 
To be noted 
Note 
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miRNA: It was reported that microRNA-146a which 
is a modulator of inflammatory signals, directly 
targets CARD10 and COPS8 (COP9 signalosome 
complex subunit 8) inhibiting the G-protein coupled 
receptor (GPRC)-mediated activation of NF-kB. It 
was also found that miR-146a represses the secretion 
of chemokines and growth factors controlled by NF-
kB. It was therefore suggested that miR-146a may 
act as a tumor suppressor by inhibiting NF-kB 
activity (Crone et al., 2012). 
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